Statinok és az emésztorendszeri daganatok

Translated title of the contribution: Statins and gastrointestinal cancers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The antitumour effect of statins has already been proven in animal experiments and human cancer cell lines in several gastrointestinal cancers. The chemopreventive mechanism is not completely clarified but the enhancement of oxidative stress, increased autophagy, altered expression of pro-and antiproliferative proteins and their influence on intracellular signaling pathways may play a role. Randomized studies, however, failed to confirme the expected results obtained from experimental studies. The goal of this review is to summarize the data available in the literature regarding the chemopreventive effects of statins on several gastrointestinal cancers. Results of clinical trials suggest that 10-20 mg statin daily has no or minimal antitumour effect. Chemopreventive effect of hydrophilic statins could not be detected but it seems to be significant in the case of hydrophobic statins. There are only few data available on the long-term daily use of 30-40 mg statins. Further long-term evaluation of the effect of statins regarding gastrointestinal cancers is needed, and an analysis of compound-and dose-related subgroups would be beneficial. Chemoprevention with statins cannot yet be accepted as standard medical practice. Use of statins as chemopreventive agents cannot be a substitute for regular oncological screening or surveillance. Orv. Hetil., 2014, 155(18), 687-693.

Original languageHungarian
Pages (from-to)687-693
Number of pages7
JournalOrvosi Hetilap
Volume155
Issue number18
DOIs
Publication statusPublished - May 1 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Gastrointestinal Neoplasms
Autophagy
Chemoprevention
Oxidative Stress
Clinical Trials
Cell Line

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statinok és az emésztorendszeri daganatok. / Sági, Veronika; Herszényi, L.; Tulassay, Z.; Gasztonyi, B.

In: Orvosi Hetilap, Vol. 155, No. 18, 01.05.2014, p. 687-693.

Research output: Contribution to journalArticle

@article{d4f9b3885153427da37145ef92c09127,
title = "Statinok {\'e}s az em{\'e}sztorendszeri daganatok",
abstract = "The antitumour effect of statins has already been proven in animal experiments and human cancer cell lines in several gastrointestinal cancers. The chemopreventive mechanism is not completely clarified but the enhancement of oxidative stress, increased autophagy, altered expression of pro-and antiproliferative proteins and their influence on intracellular signaling pathways may play a role. Randomized studies, however, failed to confirme the expected results obtained from experimental studies. The goal of this review is to summarize the data available in the literature regarding the chemopreventive effects of statins on several gastrointestinal cancers. Results of clinical trials suggest that 10-20 mg statin daily has no or minimal antitumour effect. Chemopreventive effect of hydrophilic statins could not be detected but it seems to be significant in the case of hydrophobic statins. There are only few data available on the long-term daily use of 30-40 mg statins. Further long-term evaluation of the effect of statins regarding gastrointestinal cancers is needed, and an analysis of compound-and dose-related subgroups would be beneficial. Chemoprevention with statins cannot yet be accepted as standard medical practice. Use of statins as chemopreventive agents cannot be a substitute for regular oncological screening or surveillance. Orv. Hetil., 2014, 155(18), 687-693.",
keywords = "chemoprevention, em{\'e}sztorendszeri daganatok, gastrointestinal cancers, kemoprevenci{\'o}, statin",
author = "Veronika S{\'a}gi and L. Hersz{\'e}nyi and Z. Tulassay and B. Gasztonyi",
year = "2014",
month = "5",
day = "1",
doi = "10.1556/OH.2014.29901",
language = "Hungarian",
volume = "155",
pages = "687--693",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18",

}

TY - JOUR

T1 - Statinok és az emésztorendszeri daganatok

AU - Sági, Veronika

AU - Herszényi, L.

AU - Tulassay, Z.

AU - Gasztonyi, B.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - The antitumour effect of statins has already been proven in animal experiments and human cancer cell lines in several gastrointestinal cancers. The chemopreventive mechanism is not completely clarified but the enhancement of oxidative stress, increased autophagy, altered expression of pro-and antiproliferative proteins and their influence on intracellular signaling pathways may play a role. Randomized studies, however, failed to confirme the expected results obtained from experimental studies. The goal of this review is to summarize the data available in the literature regarding the chemopreventive effects of statins on several gastrointestinal cancers. Results of clinical trials suggest that 10-20 mg statin daily has no or minimal antitumour effect. Chemopreventive effect of hydrophilic statins could not be detected but it seems to be significant in the case of hydrophobic statins. There are only few data available on the long-term daily use of 30-40 mg statins. Further long-term evaluation of the effect of statins regarding gastrointestinal cancers is needed, and an analysis of compound-and dose-related subgroups would be beneficial. Chemoprevention with statins cannot yet be accepted as standard medical practice. Use of statins as chemopreventive agents cannot be a substitute for regular oncological screening or surveillance. Orv. Hetil., 2014, 155(18), 687-693.

AB - The antitumour effect of statins has already been proven in animal experiments and human cancer cell lines in several gastrointestinal cancers. The chemopreventive mechanism is not completely clarified but the enhancement of oxidative stress, increased autophagy, altered expression of pro-and antiproliferative proteins and their influence on intracellular signaling pathways may play a role. Randomized studies, however, failed to confirme the expected results obtained from experimental studies. The goal of this review is to summarize the data available in the literature regarding the chemopreventive effects of statins on several gastrointestinal cancers. Results of clinical trials suggest that 10-20 mg statin daily has no or minimal antitumour effect. Chemopreventive effect of hydrophilic statins could not be detected but it seems to be significant in the case of hydrophobic statins. There are only few data available on the long-term daily use of 30-40 mg statins. Further long-term evaluation of the effect of statins regarding gastrointestinal cancers is needed, and an analysis of compound-and dose-related subgroups would be beneficial. Chemoprevention with statins cannot yet be accepted as standard medical practice. Use of statins as chemopreventive agents cannot be a substitute for regular oncological screening or surveillance. Orv. Hetil., 2014, 155(18), 687-693.

KW - chemoprevention

KW - emésztorendszeri daganatok

KW - gastrointestinal cancers

KW - kemoprevenció

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=84899739491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899739491&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29901

DO - 10.1556/OH.2014.29901

M3 - Article

C2 - 24776382

AN - SCOPUS:84899739491

VL - 155

SP - 687

EP - 693

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18

ER -